Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

BACKGROUND: Interleukin-2 (IL-2) serves as a pioneer of immunotherapeutic agent in cancer treatment. However, there is a considerable proportion of patients who cannot benefit from this therapy due to the limited clinical responses and dose-limiting toxicities. Mounting evidence indicates that comme...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Shi, Linlin, Sheng, Jianyong, Chen, Guozhong, Zhu, Peng, Shi, Changping, Li, Bei, Park, Chaiwoo, Wang, Jingyi, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Basic Tumor Immunology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7542661/
https://ncbi.nlm.nih.gov/pubmed/33028692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000973
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky